Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

7 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the intended use and sufficiency of the Company's cash, cash equivalents and short-term investments, the company's manufacturing and clinical trial readiness, prospects for securing a development and commercialization partner and planned phase 3 trials. Such forward-looking statements are subject to risks and uncertainties, including, among others: the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

                     Condensed Statements of Operations
                                 (unaudited)
                               (in thousands)

                                            Three Months        Nine Months
                                               Ended              Ended
                                            September 30,       September 30,
                                           2009     2008       2009     2008

    Operating expenses
      Research and development          $ 1,513  $ 1,639    $ 6,795  $ 3,621
      General and administrative            885    1,024      2,670    2,243
                                        -------  --------
    Total operating expe
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... BioTrends Research Group, Inc. finds that with the introduction ... the treatment of multiple sclerosis (MS), neurologists anticipate major shifts ... the launch of Gilenya, trial and uptake of Extavia, a ... tempered due to the perception that Extavia is a "me ...
... 2010 Prince of Wales Hospital in Hong Kong, China, ... treating cancer patients using the UNIQUE™ medical linear accelerator from ... for the first time last week, to deliver an image-guided ... in the lower part of the throat near the larynx. ...
... Scientists from Pacific Biosciences of California, Inc. (NASDAQ: ... molecule, real-time (SMRT) DNA sequencing technology to rapidly characterize ... in Haiti. Published Thursday in the New ... first whole genome sequence analysis and most detailed genetic ...
Cached Biology Technology:With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System 2Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System 3Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System 4Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... have discovered a gene in plants that disrupts fertilization ... both the female and male reproductive cells. Their ... in the journal Current Biology, has been named the ... properties. Mutations that do not allow fertilization are ...
... of Grenoble, in France, have discovered that ... by doxorubicin and trastuzumab exposures. The research ... protects against acute chemotherapy toxicity in isolated ... January 2008 issue of Experimental Biology and ...
... - A group of signaling proteins known as Wnt ... muscle and other tissues - depend on a complex ... tissue-building cell sites, according to a study at Cincinnati ... the Retromer Complex - breaks down, the delivery of ...
Cached Biology News:Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3A search for protection against chemotherapy cardiotoxicity 2Certain diseases, birth defects may be linked to failure of protein recycling system 2
... iLink makes it easy to supply microplates, ... Developed with operator convenience in mind, iLink ... ease of use. The iLink software is ... assays or sub-assays, that can be copied ...
... laboratory's requirements for data management and quality control. ... ... ... software for Staccato Systems and custom Allegro Modules allowing for the simple interface with more than ...
... demands continue to grow, the need for ... has become necessary, especially when discerning very ... innovative C1si Confocal Microscope System gives you ... capability not available in conventional confocal systems, ...
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: